Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Utafiti wa Ulinganifu wa Epigenome-Wide wa Bayesian (Bayesian EWAS)× | Utafiti wa Chama cha Epigenome-kote (EWAS)× | |
|---|---|---|
| Nyanja | Bioinformatiki | Bioinformatiki |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 2010s (framework developed ~2013–2016) | 2008–2011 (term and framework established c. 2011) |
| Mwanzilishi≠ | Multiple groups; Bayesian EWAS framework advanced by S. Richardson, P.-C. Tsai, J. T. Bell and colleagues | Rakyan, Down, Balding & Beck (conceptual framework); Illumina arrays enabled large-scale application |
| Aina≠ | Statistical association analysis | Population-scale epigenomic association study |
| Chanzo asilia≠ | Richardson, S., Tsai, P. C., Bell, J. T., & Timpson, N. J. (2016). Bayesian approaches to studying associations between epigenetic marks and phenotypes. International Journal of Epidemiology, 45(3), 694–705. link ↗ | Rakyan, V. K., Down, T. A., Balding, D. J., & Beck, S. (2011). Epigenome-wide association studies for common human diseases. Nature Reviews Genetics, 12(8), 529–541. DOI ↗ |
| Majina mbadala | Bayesian EWAS, B-EWAS, Bayesian methylation-wide association study, Bayesian epigenetic association analysis | EWAS, methylome-wide association study, epigenetic association study, DNA methylation association study |
| Zinazohusiana≠ | 4 | 5 |
| Muhtasari≠ | A Bayesian EWAS is a genome-scale association analysis that links epigenetic marks — most commonly CpG-site DNA methylation — to a phenotype or trait of interest, replacing or supplementing the classical frequentist p-value framework with a Bayesian probabilistic model. It yields posterior probabilities of association and credible intervals for each CpG site, allowing formal incorporation of prior biological knowledge and more principled handling of the multiple-testing burden intrinsic to testing hundreds of thousands of sites simultaneously. | An epigenome-wide association study (EWAS) is a hypothesis-free, genome-scale method that systematically tests whether epigenetic marks — predominantly CpG-site DNA methylation — differ between individuals with and without a trait, disease, or exposure. By scanning hundreds of thousands of genomic positions simultaneously, EWAS identifies loci where the epigenome is reproducibly associated with a phenotype, offering a layer of biological regulation that classical GWAS does not capture. |
| ScholarGateSeti ya data ↗ |
|
|